- Riethmuller C, McAleer MA, Koppes SA, Abdayem R, Franz J, Haftek M, Campbell LE, MacCallum SF, McLean WHI, Irvine AD, Kezic S, Filaggrin breakdown products determine corneocyte conformation in patients with atopic dermatitis. J ALLERGY CLIN IMMUN 2015;136 (6):1573-80.e1-2 [PubMed]
- Kezic S, O'Regan GM, Lutter R, Jakasa I, Koster ES, Saunders S, Caspers P, Kemperman PMJH, Puppels GJ, Sandilands A, Chen H, Campbell LE, Kroboth K, Watson R, Fallon PG, McLean WHI, Irvine AD, Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency. J ALLERGY CLIN IMMUN 2012;129 (4):1031-U542 [PubMed]
- Kezic S, O'Regan GM, Yau N, Sandilands A, Chen H, Campbell LE, Kroboth K, Watson R, Rowland M, McLean WHI, Irvine AD, Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity. ALLERGY 2011;66 (7):934-940 [PubMed]
- Visser MJ, Landeck L, Campbell LE, McLean WHI, Weidinger S, Calkoen F, John SM, Kezic S, Impact of atopic dermatitis and loss-of-function mutations in the filaggrin gene on the development of occupational irritant contact dermatitis. BRIT J DERMATOL 2013;168 (2):326-332 [PubMed]
- Thyssen JP, Kezic S, Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J ALLERGY CLIN IMMUN 2014;134 (4):792-799 [PubMed]
First name, surname: Sanja Kezic
Date and place of birth: 18-11-1956, Zagreb Croatia
1991-1996 Post-Doctoral Education in the field of Toxicology. Registration as certified toxicologist (National Committee for Medical-Biological Training) in the Netherlands.
1985-1990 Ph.D. in Chemistry. Faculty of Natural Sciences, University of Zagreb.
1979-1983 MSc. in Chemistry. Faculty of Natural Sciences, University of Zagreb.
1975-1979 B.Sc. in Chemistry. Faculty of Natural Sciences, University of Zagreb.
1987-present Coronel Institute of Occupational and Environmental Health. Academic Medical Center, University of Amsterdam.
Position as Senior Researcher in the field of Occupational Toxicology.
Head of the Toxicology Unit, Principal Investigator
1979-1987 Institute for Medical Research and Occupational Health, Zagreb, Clinical-Toxicology Laboratory.
Position as research assistant in the field of Occupational Toxicology and Medicine.
Project leadership/ Grants
• EU 5th Framework, 2001-2004. “Evaluation and Predictions of Dermal Absorption of Toxic Chemicals,” EDETOX project.
Co-ordinator of the ‘’In vivo Work Package’’ 250 k€
• SIG, 2008-2011:‘’Genetic susceptibility to occupational diseases
related to atopy’’
Project leader 250 k€
• NWO-STW, 2009-2013. ‘’Development of human reconstructed
models as a tool for screening purposes’’
Co-applicant of the project. 400 k€
• EU COST Network (7th Framework): 2009-2013.
‘’Skin barrier and atopic diseases’’
Coordinator and chair. 360 k€
• FES High-Tech Systems & Materials (HTS&M). 2010- .
Health Risk of manufactured nanoparticles. Bioavailability of MNPs
In vivo penetration of MNPs across skin barrier Project leader of the WP. 100 k€
• International Commission of the Occupational Health (ICOH): Secretary of the working group ‘’Occupational Dermatitis’’
• World Health Organization, (WHO: Criteria Document on ‘’Skin absorption of chemicals’’,(2005)
• CEFIC [European Chemical Industry Council]: Working Group ‘’Dermal Permeation for Human Risk Assessment’’ (2004)
• Dutch Health Council: Skin notation (2000). Intervention values for chemicals by accidents (2005)
Etiology and prevention of occupational skin diseases
This line of research focuses on the significance of variations in the filaggrin gene (FLG) for the skin barrier and the development and prognosis of occupational contact eczema. Research has also looked at whether the decomposition products of the filaggrin protein can be used as a phenotypic marker for the FLG genotype.
To study the extent to which FLG mutations contribute to the development of occupational contact eczema (CE), a prospective study is being conducted among student nurses. 500 students were included in the study in 2009. In addition to FLG mutations, the exposure of these students to skin-irritating factors during their internships will also be charted. The study will be completed in 2011.
The role of FLG mutations in the prognosis of contact eczema is being studied in collaboration with the University of Osnabruck. As part of an intervention study, started in 2009, 1000 patients with chronic CE are being examined to determine whether FLG mutations influence the prognosis of the disease.
• SIG, 2008-2011:‘’Genetic susceptibility to occupational diseases related to atopy’’ .Project leader
• NWO-STW, 2009-2013. ‘’Development of human reconstructed models as a tool for screening purposes’’ Co-applicant of the project. 400 k€
• EU COST Network (7th Framework): 2009-2013. ‘’Skin barrier and atopic diseases’’. Coordinator and chair. 360 k€
• FES High-Tech Systems & Materials (HTS&M). 2010- . Health Risk of manufactured nanoparticles. Bioavailability of MNPs. In vivo penetration of MNPs across skin barrier Project leader of the WP.
M. Soltanipoor MD MSc
Dr. R. Jurakić Tončić MSc (University of Zagreb)
Drs. F. Calkoen-Kwa
Prof. dr. M.H.W. Frings-Dresen (Occupational Diseases; Etiology and prevention of work-related diseases)
Prof. dr. J.K. Sluiter † (Medical selection and medical guidance of workers)
- Membership of medical or scientific committee, ICOH/International Conference of Occupational Health, Occupational Dermatoses
- Deb IP Limited
- University of Osnabrück